[
    [
        {
            "time": "",
            "original_text": "医疗保健：2019Q1医药板块整体增长稳健 荐9股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "2019Q1",
                    "医药板块",
                    "增长稳健"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医疗保健：2019Q1医药板块整体增长稳健 荐9股",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "瑞信：升上海医药(02607.HK)目标价至19.5港元 评级“中性”",
            "features": {
                "keywords": [
                    "瑞信",
                    "上海医药",
                    "目标价",
                    "19.5港元",
                    "中性"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "瑞信：升上海医药(02607.HK)目标价至19.5港元 评级“中性”",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "三大千亿药商业绩PK：国控稳居第一 上药超越华润",
            "features": {
                "keywords": [
                    "药商",
                    "国控",
                    "上药",
                    "华润",
                    "业绩PK"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "三大千亿药商业绩PK：国控稳居第一 上药超越华润",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]